Blar i Bergen Open Research Archive på forfatter "Guren, Tormod Kyrre"

Viser treff 1-5 av 5

    • Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer 

      Hamfjord, Julian; Guren, Tormod Kyrre; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per; Dajani, Olav; Lingjærde, Ole Christian; Tveit, Magne Kjell; Pallisgaard, Niels; Spindler, Karen-Lise Garm; Kure, Elin Wenche Hegland (Journal article; Peer reviewed, 2021)
      Detection of tumour-specific circulating cell-free DNA in plasma (ctDNA) fails in a significant number of cases depending on the clinical context. The primary aim was to investigate clinicopathological factors associated ...

    • Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment 

      Aamdal, Elin; Skovlund, Eva; Jacobsen, Kari Dolven; Straume, Oddbjørn; Kersten, Christian; Herlofsen, Oluf; Karlsen, Jarle; Hussain, Israr; Amundsen, Anita; Dalhaug, Astrid; Nyakas, Marta Sølvi; Hagene, Kirsten Thorin; Holmsen, Kjersti; Aamdal, Steinar; Kaasa, Stein; Guren, Tormod Kyrre; Kyte, Jon A (Journal article; Peer reviewed, 2022)
      Background: We have previously reported that the safety and efficacy of ipilimumab in real-world patients with metastatic melanoma were comparable to clinical trials. Few studies have explored health-related quality of ...

    • Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway 

      Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne; Berg, Thomas; Bjørge, Line; Blix, Egil Støre; Bjerkehagen, Bodil; Brabrand, Sigmund; Dalhaug, Astrid; Dietzel, Dalia; Dønnem, Tom; Enerly, Espen; Flobak, Åsmund; Fluge, Sverre; Gilje, Bjørnar; Gjertsen, Bjørn Tore; Grønberg, Bjørn Henning; Grønås, Kari; Guren, Tormod Kyrre; Hamre, Hanne Mari; Haug, Åse; Heinrich, Daniel; Hjortland, Geir Olav; Hovig, Eivind; Hovland, Randi; Iversen, Ann-Charlotte; Janssen, Emiel; Kyte, Jon A; Gythfeldt, Hedda; Lothe, Ragnhild Adelheid; Lund, Jo-Åsmund; Meza, Leonardo Zepeda; Munthe-Kaas, Monica Cheng; Nguyen, Olav Toai Duc; Niehusmann, Pitt; Nilsen, Hilde; Puco, Katarina; Ree, Anne Hansen; Riste, Tonje Bøyum; Semb, Karin; Steinskog, Eli Sihn Samdal; Stensvold, Andreas; Suhrke, Pål; Tennøe, Øyvind Krohn; Tjønnfjord, Geir Erland; Vassbotn, Liv Jorunn; Aas, Eline; Aasebø, Kristine Øverås; Tasken, Kjetil; Smeland, Sigbjørn; Cameron, Marte Grønlie (Journal article; Peer reviewed, 2022)
      Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed ...

    • Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up 

      Aamdal, Elin; Jacobsen, Kari Dolven; Straume, Oddbjørn; Kersten, Christian; Herlofsen, Oluf; Karlsen, Jarle; Hussain, Israr; Amundsen, Anita; Dalhaug, Astrid; Nyakas, Marta Sølvi; Schuster, Cornelia; Hagene, Kirsten Thorin; Holmsen, Kjersti; Russnes, Hege Elisabeth Giercksky; Skovlund, Eva; Kaasa, Stein; Aamdal, Steinar; Kyte, Jon A.; Guren, Tormod Kyrre (Journal article; Peer reviewed, 2022)
      Ipilimumab was the first treatment that improved survival in advanced melanoma. Efficacy and toxicity in a real-world setting may differ from clinical trials, due to more liberal eligibility criteria and less intensive ...

    • Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy 

      Hamfjord, Julian; Guren, Tormod Kyrre; Dajani, Olav; Johansen, Julia Sidenius; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per; Lingjærde, Ole Christian; Tveit, Magne Kjell; Kure, Elin Wenche Hegland; Pallisgaard, Niels; Spindler, Karen-Lise Garm (Peer reviewed; Journal article, 2019-05-02)
      Background: Metastatic colorectal cancer (mCRC) is a heterogeneous disease where prognosis is dependent both on tumor biology and host factors. Total circulating cell-free DNA (cfDNA) has shown to harbor prognostic information ...